(RTTNews) - Medical technology company, AngioDynamics, Inc. (ANGO) on Thursday announced the appointment of Eric Honroth as President and Chief Executive Officer (CEO) and a member of its Board of Directors, effective November 2, 2026.

AngioDynamics Names Honroth As CEO, Clemmer To Retire; Stock Down In Premarket 

Fintel reports that on October 7, 2026, Barclays initiated coverage of Boston Scientific (NYSE:BSX) (BATS-CHIXE:BSXD) with a Equal-Weight recommendation.Boston Scientific Corporation, based in the United States, predominantly operates in the medical devices industry. The company

Barclays Initiates Coverage of Boston Scientific with Equal-Weight

(RTTNews) - Boston Scientific Corp. (BSX), a medical technology company, on Wednesday announced that it has appointed Joseph M. Fitzgerald as Executive Vice President and Chief Operating Officer (COO), effective January 1, 2027.

Boston Scientific Names Fitzgerald Executive Vice President & COO In New Operating Restructure 

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, FedEx Corp (Symbol: FDX) has taken over the #181 spot from Boston Scientific Corp. (Symbol: BSX), according to The Online Investor.  

	Market capitalization is an import

FedEx Takes Over #181 Spot From Boston Scientific 

The ROBO Global Healthcare Technology and Innovation ETF is seeing unusually high volume in afternoon trading Friday, with over 454,000 shares traded versus three month average volume of about 27,000.  Shares of HTEC were trading flat on the day.

Components of that ETF with the

Friday's ETF with Unusual Volume: HTEC  

Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestitureThe Company is now fully funded through the first year of the expected NXT-41x launch and into 2029 GAITHERSBURG, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix t

Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Corporation News